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Abstract. 
Introduction: Trastuzumab, a recombinant humanized monoclonal antibody, targets the ex-
ternal domain of HER2 to improve the efficacy of HER2-positive breast cancer treatment and 
inhibit carcinoma cellular proliferation. The purpose of this study was to identify early changes 
in cardiac function and dimensional changes in heart size in patients treated with trastuzumab. 
Materials and Methods: Seventy three female patients with Her2/neu overexpression (IHC 
3+/Fish +) in breast cancer underwent echocardiography before and after trastuzumab therapy.  
Results: Cardiac complications developed in 14 patients (19.2%), including asymptomatic left 
ventricle systolic dysfunction (n = 12), symptomatic heart failure (n = 2), new asymptomatic 
left bundle branch block (n = 1), new negative T waves on electrocardiogram (n = 2), pericar-
dial effusion (n = 1), and death (n = 1). No significant deterioration in diastolic function was 
noted, and right heart diameters and function did not change significantly. Most patients re-
mained in an asymptomatic stage of cardiac disease. A significant decrease in left ventricular 
ejection fraction (LVEF) was observed in 14 patients (19.2%), and new mitral regurgitation (≥ 
grade 1) was noted after 3 months of trastuzumab therapy in 7 patients (9.6%).  
Conclusions: Trastuzumab led to measurable decreases in LVEF (but only 2.7% was symp-
tomatic heart failure) and new mitral regurgitation. Therefore, regular follow-up with echo-
cardiography is essential for early detection and prevention of trastuzumab-induced cardio-
myopathy. 
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中文摘要 
目的：本研究是研究乳癌病患在賀癌平(Trastuzumab)治療後之心臟功能及心臟大小之早期
改變。 
材料和方法：研究 73 位人類表皮生長因子受體 2（HER2）過度表現之乳癌女性病患在賀
癌平治療前後之心臟超音波變化；研究期間於西元 2007 年 10 月起至 2013 年 9 月；心血
管危險因子之分析包括年齡、身體質量比(BMI)、抽煙與否、有無高血壓、生活型態、有
無乳癌家族史、有無高血脂、有無糖尿病、有無憂鬱、有無使用血管轉換抑制劑或血管
張力素受體阻斷劑或乙型阻斷劑之使用。 
結果：心臟相關之併發症發生於 14 位病患(19.2%)，包括無症狀之左心室收縮異常(n=12)，
有症狀之心臟衰竭(n=2)，新發生無症狀之左束支傳導阻滯 (n=1)，心電圖上新發生之負 T 
波變化(n=2)，心包膜積水(n=1)，和死亡(n=1)。而心臟舒張功能及右心室大小功能並無明
顯變化。大部份乳癌病患經賀癌平治療後維持在無症狀之心臟功能狀態。明顯之左心室
收縮功能下降發生於 14 位病患(19.2%)，和三個月後明顯的二尖瓣逆流(≥ grade 1) 發生於
9 位病患(9.6%)。 
結論：賀癌平之使用可能會導致左心室收縮功能下降(但僅 2.7% 會產生有症狀的心臟衰
竭)和明顯的二尖瓣逆流，故在治療期間定期心臟超音波監測是必要的。 
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INTRODUCTION 
Breast cancer is the most common cancer in 
women and the leading cause of cancer-related deaths 
worldwide. Up to 25% of women with early breast 
cancer have human epidermal growth factor receptor 2 
(HER2)-positive disease, which is associated with 
aggressive disease, a higher chance of recurrence after 
initial treatment, and a poor prognosis [1,2]. 
Trastuzumab is a recombinant humanized mono-
clonal antibody which targets the external domain of 
HER2 to improve the efficacy of HER2-positive 
breast cancer treatment and inhibit carcinoma cellular 
proliferation. Four large multicenter randomized trials 
revealed that trastuzumab in HER2-positive breast 
cancer added to anthracycline, cyclophosphamide, or 
paclitaxel chemotherapy resulted in a 50% reduction 
in 3-year risk of recurrence and a reduction of over a 
30% in mortality [4,5]. Those benefits were recently 
confirmed by longer follow-up studies [6]. 
Contrary to the irreversible cardiomyocyte damage 
caused by anthracycline, trastuzumab-mediated cardi-
otoxicity seems to be reversible [7]. The observation 
of cardiac functional recovery after exposure to 
trastuzumab led to the description of “chemotherapy- 
related cardiac dysfunction” or CRCD [8]. Cardio-
vascular toxicity following breast cancer treatments 
with trastuzumab may manifest as hypertension, 
rhythm disturbances, ischemic heart disease, throm-
boembolic events, or congestive heart failure (CHF). 
The incidence of cardiotoxicity was highest in patients 
receiving concurrent trastuzumab and anthracycline 
(27%), with a lower risk in patients receiving 
trastuzumab and either paclitaxel (13%) or 
trastuzumab alone (3-7% in metastatic disease) [9]. 
Monitoring of the left ventricular ejection fraction 
(LVEF) is the current standard for detection of 
trastuzumab-induced cardiotoxicity, and trastuzumab- 
induced cardiotoxicity was defined as a decrease in 
LVEF of ≥ 15% or to a value < 50%. A clinically sig-
nificant decrease in LVEF was observed in 28.6% of 
women receiving trastuzumab therapy [9]. 
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The purpose of this study was to estimate 
trastuzumab-associated cardiac side effects in HER2 
positive breast cancer patients after completion of 
trastuzumab therapy either in the adjuvant or neoad-
juvant setting and with or without radiotherapy in 
Taiwanese women. 
 
Materials and Methods 
 
Study Design 
This open-label, observational study was per-
formed at a single medical center in Northern Taiwan 
to evaluate the cardiac safety of trastuzumab in wom-
en with HER2-positive breast cancer. All patients 
were diagnosed with histologically confirmed breast 
cancer with HER2 overexpression, Trastuzumab was 
used for adjuvant therapy in 11 patients and neoadju-
vant therapy in 8 patients and there were also 13 pa-
tients who used trastuzumab when their disease had 
metastasized. The loading administration dose of 
trastuzumab was 8 mg/kg of body weight, and the 
maintenance dose was 6 mg/kg every 3 weeks for a 
total dose of 5,720 mg-6,600 mg. Trastuzumab was 
discontinued in patients who developed significant 
cardiotoxicity, which was defined as a potentially 
life-threatening cardiac event. 
Anthracycline-containing regimens used as either 
adjuvant or neoadjuvant chemotherapy was AC (i.e., 
doxorubicin 60 mg/m2 and cyclophosphamide 600 
mg/m2 every 3 weeks for four cycles). Docetaxel 
(60-75 mg/m2) was administered three times weekly. 
Endocrine therapy was added as clinically indicated 
based on tumor biology behavior, and radiotherapy 
was administered concurrent with trastuzumab in 35 
individuals (47.9%). All participants provided in-
formed consent. 
Table 1. Risk factors in the overall patient population and in patients either with or without cardiac complications # 
Risk factors 
 
Overall  patient 
population (n=73 ) 
No cardiac   
complications (n=59) 
Cardiac complications  
(n=14 ) 
P value* 
Age (years) 54.7 ± 11.9 50.1 ± 10.9 65.5 ± 13.5 0.06 
Hypertension 15 (20.54%) 11 (18.64%) 4 (28.57%) 0.82 
Diabetes mellitus 7 (9.59%) 5 (8.47%) 2 (14.29%) 0.89 
Smoking 7 (9.59%) 5 (8.47%) 2 (14.29%) 0.89 
Hypercholesterolemia 22 (30.14%) 18 (30.51%) 4 (28.57%) 0.78 
Sedentary life style 46 (63.01%) 38 (64.41%) 8 (57.14%) 0.91 
Body mass index (BMI, 
kg/m2) 
26.81 ±4.52 26.92 ±4.63 27.33 ±4.41 0.95 
Overweight (BMI 
between 25 to 30) 
9 (12.33%) 6 (10.17%) 3 (21.43%) 0.66 
Obesity (BMI ≥ 30) 6 (8.22%) 4 (6.78%) 2 (14.29%) 0.65 
Depression 8 (10.96%) 6 (10.17%) 2 (14.29%) 0.94 
Positive family history 25 (34.25%) 18 (30.51%) 7 (50.00%) 0.88 
ACE-I/ARB (at baseline) 12 (16.38%) 10 (16.95%) 2 (14.29%) 0.92 
β-Blockers (at baseline) 9 (12.33%) 6 (10.17%) 3 (21.43%) 0.71 
#Cardiac complications included asymptomatic left ventricle dysfunction, symptomatic heart failure, significant changes of 
electrocardiograms, and pericardial effusion 
*P value compares the groups with and without cardiac complications 
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Patient Characteristics 
This study included 73 consecutive patients with 
HER2 overexpression and who qualified for 
trastuzumab chemotherapy. Female patients ≥ 20 
years of age who were treated at the Shin-Kong Wu 
Ho-Su Memorial Hospital beginning in October 2007 
were eligible. The mean age at inclusion was 51.7 ± 
12 years (range, 31-83 years). The sedentary lifestyle 
was defined as a type of lifestyle with no or irregular 
physical activity. Sedentary activities include sitting, 
reading, watching television, playing video games, 
and computer use for much of the day with little or no 
vigorous physical exercise. 
 
Outcome Measures 
The following cardiovascular risk factors were an-
alyzed: age, body mass index (BMI) between 25 
kg/m2 and < 30 kg/m2, BMI > 30 kg/m2, smoking, 
hypertension, sedentary lifestyle, positive family his-
tory, hypercholesterolemia, diabetes mellitus, de-
pression, positive family history, and angiotensin-    
converting enzyme inhibitors/angiotensin receptor 
blockers (ACE-I/ARB) and β-blocker usage (Table 1). 
Exclusion criteria included prior anti-HER2 treatment, 
prior adjuvant anthracycline-containing chemotherapy, 
prior high-dose chemotherapy with peripheral 
stem-cell transplantation, history of malignancy, se-
rum creatinine > 1.5 upper limit of normal (ULN), 
bilirubin > 1.5 ULN, either transaminases or alkaline 
phosphatase > 2.5 ULN or > 5.0 ULN, respectively, in 
case of either liver or bone metastases, serum calcium 
> 512.0 mg/dL (3.0 mmol/L), pregnancy, lack of a 
reliable appropriate contraceptive method in women 
of child-bearing potential, or any medical condition 
likely to interfere with the conduct of the study. In 
addition, specific cardiovascular exclusion criteria 
were an LVEF < 55% determined by two-dimensional 
echocardiography at rest, prior treatment with cardio-
toxic agents, valvular heart disease requiring treatment, 
cardiomyopathy, acute myocarditis, CHF, end-diastolic 
left ventricular diameter > 56 mm determined by 
M-mode echocardiography at rest, arrhythmias re-
quiring treatment, poorly controlled arterial hyperten-
sion, or prior mediastinal irradiation. The breast can-
cer patients were regularly followed-up at the hospi-
tal’s general surgery outpatient department after 
trastuzumab therapy was terminated every 3 months 
for at least 1 year. 
Cardiovascular system evaluation (history, cardi-
ovascular risk factors, blood pressure, and physical 
examination), electrocardiography, and echocardiog-
raphy were performed at baseline and repeated every 3 
months until trastuzumab termination. The evaluation 
was performed and interpreted by the same experi-
enced cardiologists throughout the study period. Fur-
ther, standard of care serial echocardiographic scans 
were performed to assess left ventricular contractile 
function at baseline and again 3 month and 6 month 
after trastuzumab initiation. Parasternal and apical 
views were obtained using a standard echocardio-
graphic machine (Philips IE 33). The LVEF was de-
termined from two-dimensional images according to 
established criteria, including the modified Simpson’s 
method. For study purposes, clinically important car-
diotoxicity was defined as a decrease in ejection frac-
tion (EF) of ≥ 15% from baseline or to a value < 50%. 
All other patients were categorized as normal LVEF. 
Clinically relevant changes were treated via best clin-
ical practice according to the managing general sur-
geon. 
 
Tumor Characteristics 
Tumor histology, stage, grading, receptor status 
(HER2 score), and antigen background (estrogen re-
ceptor, progesterone receptor) were recorded. Most 
patients had an invasive ductal growing pattern 
(98.6%). The majority of tumors at the time of dis-
covery were at stage I~II and 65 patients (89%) were 
at Her2-neu receptor over-expression. Patients with a 
HER2 2+ (IHC score) underwent further fluorescent 
in situ hybridization test (FISH) (Table 2). HER2 sta-
tus was determined using archived primary tumor 
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samples and either a standard semi-quantitative im-
munohistochemistry test (DAKO HercepTest TM) or 
FISH analysis (Vysis or Ventana). 
 
Chemotherapy before Adjuvant 
Trastuzumab Therapy 
Seventy-three patients received adjuvant chemo-
therapy with different protocols before initiating ad-
juvant trastuzumab treatment. Twelve patients (16.4%) 
with advanced tumor were treated with trastuzumab 
and oral capcitamin (Xeloda). Taxotere was used in 
combination in 31 patients (42.5%), cyclophospha-
mide was part of a chemotherapy combination treat-
ment in 29 patients (39.7%), and epirubicin was used 
in combination in 18 patients (24.7%). Both adjuvant 
and neoadjuvant were included in our study. 
 
Trastuzumab Treatment 
All patients received an initial infusion of 
trastuzumab (8 mg/kg body weight) dissolved in so-
dium chloride 0.9% over a 60 min period and fol-
lowed infusions at 6 mg trastuzumab/kg body weight 
every 3 weeks. 
On day 1, IV trastuzumab, epirubicin, and cyclo-
phosphamide were administered according to standard 
prescribing information. Trastuzumab was withheld in 
the event of drug-related grade 3 or 4 non-hematologic 
toxicity until recovery to grade 2 or better. In the 
event of recurrence of grade 3 or 4 nonhematologic 
toxicity, trastuzumab was to be discontinued. 
A combination of epirubicin (60 mg/m2) and cy-
clophosphamide (600 mg/m2) administered every 3 
weeks for six cycles then for four to six cycles at a 
higher dose level (epirubicin at 90 mg/m2 and cyclo-
phosphamide at 600 mg/m2). Epirubicin was adminis-
tered intravenously over 30 minutes and was followed 
by intravenous cyclophosphamide over 30 minutes. 
The first dose of chemotherapy was administered 3 
Table 2. Tumor characteristics in the study population 
Tumor characteristics Classification No. of patients % 
Histology Invasive ductal carcinoma 72 98.6% 
 Invasive lobular carcinoma 0 0 
 Others (mucinous carcinoma) 1 1.4% 
Stage T0 4 5.4% 
 T1 11 15.1% 
 T2 39 53.4% 
 T3 14 19.2% 
 T4 5 6.8% 
Lymph node N0 25 34.2% 
 N1 23 31.5% 
 N2 16 21.9% 
 N3 9 12.3% 
Distant metastasis M1 13 17.8% 
HER2 score 2+ 8 11.0% 
 3+ 65 89.0% 
Hormone receptor  (+) ER (+)/PR (+/-) 68 93.2% 
Hormone receptor  (-)  5 6.8% 
ER, estrogen receptor; PR, progesterone receptor 
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hours after trastuzumab, and subsequent doses were 
administered immediately after trastuzumab if the ini-
tial dose was well tolerated. Patients were scheduled 
to receive all cycles of chemotherapy at the same dose. 
Treatment could be postponed for a maximum of 1 
week only in the event of severe hematological and/or 
nonhematologic toxicity. If there was no improvement 
in toxicity during that period, chemotherapy was dis-
continued. 
Palliative and supportive care for disease- and 
treatment-related symptoms (e.g., analgesics, para-
centesis, premedication and hydration) was offered to 
all patients when indicated, and palliative radiotherapy 
was permitted if it did not compromise evaluation of 
disease response Any drug, except antineoplastic 
drugs/agents, dextrazoxane, or prophylactic granulo-
cyte colony-stimulating factor (G-CSF) could be ad-
ministered concomitantly. 
 
Clinical Assessment 
Prior to trastuzumab treatment and every 3 months 
thereafter, each patient obtained a complete medical 
assessment. Symptoms of heart failure were assessed, 
and during the follow-up examination, patients were 
asked about clinically relevant worsening of cardiac 
function, especially dyspnea, palpitations, and edema. 
LVEF was measured by two-dimensional echo-
cardiography, examinations were recorded, and the 
long-axis view was used to assess EF in all patients. 
For the echocardiograms, all patients underwent a 
transthoracic two-dimensional echocardiography ac-
cording to the guidelines of echocardiography [10]. To 
determine diastolic function, pulsed Doppler tracings 
of mitral inflow, pulsed Doppler tracings of the right 
upper pulmonary vein, and tissue Doppler imaging 
(TDI) records of the mitral valve annulus were ob-
tained. The Simpson rule was used to calculate LVEF 
and LV systolic and diastolic volumes [11]. The frac-
tional shortening (FS) was also used for estimating 
LVEF. All echocardiographic examinations were per-
formed with a conventional echocardiographic system 
(Philip IE33 and a cardiac transducer 1.5-4.0 MHz). 
 
Cardiac Monitoring and Cardiotoxicity 
A physical examination, cardiac questionnaire, 
electrocardiogram (ECG), and an assessment of LVEF 
by echocardiography were executed at baseline and 3 
months and 6 months and when clinically required 
(Table 3). 
Patients with completely excised HER2-positive 
breast cancer were eligible for the study if they had 
completed at least four cycles of a standard (neo) ad-
juvant chemotherapy regimen and radiotherapy (if 
applicable). 
Significant cardiotoxicity was regarded as a poten-
tially life-threatening cardiac event and was defined 
using the following criteria: absolute decrease of 
LVEF > 15% [12], absolute reduction in LVEF < 50% 
[13], and any symptoms/signs of heart failure. As oth-
er events occurring in the cardiovascular system dur-
ing trastuzumab treatment are rare and not well known, 
patients were carefully evaluated by both the cardiol-
Table 3. Left ventricular ejection fraction (LVEF) in the total patient population and in patients either with or 
without cardiac complications at particular time points 
Time of 
measurement 
Total patient population 
LVEF (%) (73 p’t)  
No cardiac complications 
LVEF (%) (59 p’t) 
Cardiac complications  
LVEF (%) (14 p’t) 
P value* 
Baseline 67.36 ± 7.27 66.08 ± 6.76 72.31 ± 6.87 0.77 
3 months 61.47 ± 9.46 64.98 ± 6.60 46.64 ± 3.33 0.01 
6 months 61.42 ± 9.52 65.18 ± 6.61 46.69 ± 1.64 < 0.01 
* P value compares the groups with and without cardiac complications 
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ogist and oncologist during the course of the treatment. 
If significant cardiotoxicity developed, trastuzumab 
was discontinued early. The decision regarding termi-
nation of trastuzumab was made according to accepted 
guidelines [14,15] and following consultation with the 
supervising cardiologist. In the majority of cases of 
significant cardiotoxicity, trastuzumab was discontin-
ued and heart failure (HF) treatment with ACE-I/ARB 
and/or β-blockers was initiated and adjusted to 
achieve the maximum tolerable doses. Additional car-
diac treatment, including diuretics, anticoagulants, and 
antiarrhythmic drugs, was administered as required by 
the clinical situation, based on the current standard of 
care [16]. 
 
Statistical Analysis 
Data were reported as mean ± standard deviation. 
Comparisons between groups were made using the 
unpaired Student’s t test for continuous variables and 
by either the χ2 test or Fisher exact test (as appropriate) 
for categorical variables. Univariate regression analy-
sis was used to identify covariates of cardiotoxicity. A 
probability value of < 0.05 was considered statistically 
significant. SPSS release 17.0 (SPSS, Chicago, IL) 
was used for statistical analysis. 
 
RESULTS 
A total of 73 patients diagnosed with HER2-  
positive early stage breast cancer/metastatic breast 
cancer and eligible for trastuzumab adjuvant therapy 
were identified. All 73 patients reached the 3 month 
follow-up examination, and 65 patients reached the 6 
month follow-up visit. Patients were divided into two 
groups based on observed cardiotoxicity, as defined 
above in terms of declining LVEF. The group with 
cardiac complication (n = 14) was older than group 
without cardiac complication (n = 59), but the differ-
ence was not statistically significant (65.5 ± 13.5 years 
vs 50.1 ± 10.9 years, p = 0.06, respectively) as de-
scribed in Table 1. Most patients remained in an 
asymptomatic stage of cardiac disease. Only two pa-
tients developed dyspnea New York Heart Association 
II, and only three patients reported paroxysmal palpi-
tations. In this study, 14 of the 73 women (19.2%) 
treated with trastuzumab experienced a clinically im-
portant decrease in LVEF following initiation of 
treatment. In the present study, we found that the pa-
tients with cardiac complication (n = 14) compared 
Table 4. LA size and mitral regurgitation status in the total patient population and in patients either with our 
without cardiac complications at particular time points 
Variable and time of 
measurement 
Total patient  
Population (73 p’t) 
No cardiac  
complications (59 p’t) 
Cardiac complications 
(14 p’t) 
P value* 
Left atrial size     
Baseline (mm) 35.15 ± 5.17 34.75 ± 5.26 36.57 ± 4.45 0.85 
3 months (mm) 38.13 ± 5.31 35.51 ± 5.42 42.50 ± 5.49 0.67 
6 months (mm) 40.34 ± 5.23 37.12 ± 6.68 45.31 ± 3.58 0.61 
Mitral regurgitation     
Baseline (% and 
number of patients) 
24.66% (18/73) 20.33%  (12/59) 42.85% (6/14) 0.08 
3 months (% and 
number of patients) 
34.24% (25/73) 22.03%  (13/59) 85.71%  (12/14) < 0.001 
6 months (% and 
number of patients) 
33.84% (22/65) 18.86%  (10/53) 91.66%  (11/12) < 0.001 
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with no cardiac complication (n = 59) had more de-
pressed LVEF in the trastuzumab treatment in the 3rd 
month (46.64 ± 3.30 vs 64.98 ± 6.60; p = 0.01) and in 
the 6th month (46.69 ± 1.64 vs 65.18 ± 6.61; p <0.01). 
Most patients with cardiac dysfunction recovered 
after 6 months. Patients with trastuzumab-associated 
cardiac dysfunction were treated with ACE-I/ARB 
and/or β-blockers, which were administered at the 
maximal tolerable dose [16]. Left atrial diameter ge-
ometry changed during the early periods of 
trastuzumab treatment. Specifically, the median left 
atrial diameter in the group of patients with cardiac 
complications increased compared to the group with 
the no cardiac complications after trastuzumab treat-
ment (from 35.51 ± 5.4 mm to 42.5 ± 5.49 mm after 3 
months, p = 0.67 and from 37.12 ± 6.68 mm to 45.31 
± 3.58 mm, p = 0.61 after 6 months of trastuzumab 
treatment), but that difference was not statistically 
significant (Table 4). In addition to the transformation 
of the left atrial geometry, an increased percentage of 
mitral valve regurgitation after trastuzumab treatment 
in the group of patients with cardiac complications 
was noted, which was statistically different between 
the two groups of patients after 3 months of 
trastuzumab treatment (22.0% vs. 85.7%, p < 0.001) 
and 6 months (18.9% vs. 91.7%, p < 0.001 ) as shown 
in Table 4. 
There was no significant difference between pa-
tients with normal and decreased LVEF based on either 
BMI or frequency of other known risk factors for car-
diac dysfunction such as hypertension, diabetes, hy-
percholesterolemia, coronary artery disease, a sedentary 
life style, smoking, or use of antihypertensive medica-
tions (i.e., ACE-I/ARB, ß-blockers) as illustrated in 
Table 1. One patient (65 years old, stage T3N2M1, with 
radiation treatment and anti-hypertensive treatment) 
associated with trastuzumab-related death was noted 
during the 3rd treatment course (in the same night just 
after trastuzumab infusion 4 hours later). The other 
patient (63 years old, stage T4N2M1, with radiation 
treatment, with diabetic mellitus under oral hypogly-
cemic agents treatment) presented dyspnea discomfort 
after trastuzumab infusion (the 4th treatment course) 
and more dyspnea thereafter then developed small to 
moderate amount of pericardial effusion 1 week later, 
confirmed by echocardiogram, was treated by diuretic 
and recovery after 1 week later. Both of them were 
healthy and without heart disease history previously. 
 
DISCUSSION 
Cardiotoxicity, defined as a decrease in LVEF, has 
been observed following trastuzumab adjuvant treat-
ment combined with standard chemotherapy in as 
many as 27-34% of patients [9,17,18]. Interestingly, 
the incidence of cardiotoxicity was lower in the cur-
rent study, which found that only 19.2% of women 
(14/73) enrolled in this study who were treated with 
trastuzumab experienced a clinically significant de-
crease in LVEF. Rates of cardiotoxicity are somewhat 
lower in newer adjuvant trials of trastuzumab, but 
likely underestimate risk due to careful selection of 
patients to minimize cardiac events by excluding pa-
tients with underlying cardiac disease or abnormal 
baseline/postanthracycline treatment LVEF [17]. The 
highest incidence of cardiac side effects was observed 
in patients treated with a combination of anthracycline, 
cyclophosphamide, and trastuzumab (27%) followed 
by the group of patients treated with a combination of 
trastuzumab and paclitaxel (13%). In contrast, mono-
therapy with trastuzumab led to cardiac adverse events 
in only 4% of patients [19]. The clinical symptom of 
those cardiac adverse events was dyspnea and NYHA 
III or IV. In patients with adjuvant trastuzumab thera-
py subsequent to chemotherapy with anthracycline 
and cyclophosphamide, cardiac dysfunction occurred 
in only 9% of all patients [20]. The mechanisms of 
trastuzumab-related cardiotoxicity are still being dis-
cussed intensively, but appear to differ from those re-
lated to anthracyclines. Specifically, trastuzumab does 
not seem to cause myocyte loss. In patients with 
trastuzumab cardiac dysfunction, myocytes appear 
histologically normal, and changes can only be seen 
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via electron microscopy, consistent with a reversible 
cardiomyopathy [21]. That finding led to the classifi-
cation of type II cardiotoxicity as opposed to the irre-
versible changes associated with anthracycline (type I 
cardiotoxicity). Unlike anthracycline toxicity, it has 
been shown that trastuzumab cardiotoxicity is not 
dose dependent, is reversible upon therapy withdrawal, 
and the drug can be safely re-administered after re-
covery of EF. In type I cardiotoxicity, the earliest 
damage is myofibrillar disorganization that is likely to 
progress to myocyte apoptosis and necrosis. When HF 
occurs, the clinical picture may stabilize, but the 
damage appears to be permanent and irreversible. 
Further, disease relapse months to years after type I 
cardiotoxicity can be correlated with sequential cardi-
ac stress [8], whereas EF is likely to recovery in type 
II cardiotoxicity, and there is evidence of relatively 
safe re-administration after discontinuation. Unlike 
anthracyclines, there is a low likelihood of HF in-
duced by sequential stress [22]. The Herceptin Adju-
vant HERA trial demonstrated severe cardiotoxicity, 
including one cardiac death and nine patients with 
severe congestive heart failure in only 0.5% of women 
with adjuvant trastuzumab treatment for 12 months or 
24 months [13]. More than 70% of patients received a 
chemotherapy combination with epirubicin in differ-
ent study protocols before adjuvant trastuzumab 
treatment began. 
In the predominantly echocardiography-based 
study reported herein, the authors focused on systolic 
function and geometrical changes during the early 
months of trastuzumab treatment. In this study cohort, 
no patient had to interrupt the adjuvant therapy due to 
worsening of heart function and/or heart failure. Dur-
ing the observation period, only some patients devel-
oped symptoms of heart failure (i.e., NYHA I and II), 
yet no patient fulfilled the Cardiac Review and Evalu-
ation Committee (CREC) criteria for discontinuing the 
adjuvant trastuzumab treatment, despite the fact that 
one patient died during trastuzumab treatment [9]. The 
study authors observed an increase in left atrial diam-
eter index and an increase in mitral regurgitation iden-
tified by echocardiography. 
The Framingham Heart Study revealed an associa-
tion between increasing left atrial size and increasing 
age, left ventricle mass, hypertension, atrial fibrilla-
tion, congestive heart failure or myocardial infarction, 
mitral annular calcification, and diabetes. In addition, 
left atrial enlargement led to an increasing relative risk 
of death in both genders [24]. In hypertensive patients, 
left atrial (LA) enlargement is associated with higher 
incidence of cardiovascular death and stroke [25], and 
LA volumes increase to augment active LA emptying 
even in patients with mild hypertension [23]. Further, 
according to recently published data from the VAL-
IANT echo study of patients after myocardial infarc-
tion, an independent association between LA volume 
index (LAVI) and the combined endpoints either 
death or hospitalization for heart failure and overall 
mortality was found [11]. 
In the present study, we found an increased degree 
of mitral regurgitation. It remained unclear if mitral 
regurgitation either induced LA enlargement or was a 
consequence of LA enlargement. However, a few 
signs, such as the unchanged reservoir function and 
the increasing mitral regurgitation from mild to mod-
erate, pointed toward LA enlargement having devel-
oped earlier followed by mitral regurgitation. The di-
astolic heart functional values in the study cohort did 
not change significantly during the observation period. 
Overall, nearly one in five patients will discontin-
ue trastuzumab treatment due to cardiac complications, 
among which LV dysfunction is the most frequent 
abnormality. Although cardiac complications of 
trastuzumab therapy are frequent, they do not seem to 
be permanent. Instead, most cardiac complications are 
transient, asymptomatic, and reversible; however, 
there are reports of rare cases of progressive LV dys-
function and HF. Nevertheless, longer follow-up is 
needed to confirm that cardiotoxicity associated with 
trastuzumab therapy does not affect long-term out-
come. Prior to institution of trastuzumab therapy, all 
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patients should be evaluated for cardiovascular status. 
As the majority of complications are asymptomatic, 
routine cardiac monitoring should be performed dur-
ing trastuzumab treatment.  
Major adverse cardiopulmonary events in our 
study were sudden death (1 patient) and pericardial 
effusion (1 patient). In our study, one patient devel-
oped dyspnea and small to moderate pericardial effu-
sion was noted by echocardiogram 1 week later. In 
most case reports about trastuzumab related pericardi-
al effusion [26,27], most case reports were small 
self-limiting and easy to medically control. There was 
a report about ventricular tachycardia associated with 
trastuzumab in a patient with preserved LV systolic 
function that resulted in sudden cardiac death [28]. 
An important limitation of this study was the small 
number of patients and the different therapeutic re-
gimes used before starting the adjuvant trastuzumab 
treatment. Regardless, 24.7% of included patients re-
ceived epirubicin in combination with different 
chemotherapeutics, and 39.7% of all treatment re-
gimes included cyclophoshamide. Another major lim-
itation of this study was the use of decreased LVEF as 
a surrogate for cardiotoxicity. In the United States, 
only 50% of patients diagnosed with heart failure ac-
tually had decreased LVEF [29-31], and the overall 
cardiac outcomes of heart failure patients with and 
without decreases LVEF were similar [31]. The long- 
term implication of asymptomatic changes in LVEF 
are unclear [17,32]. 
 
CONCLUSIONS 
The blockade of Her2-neu receptors with 
trastuzumab in patients with breast cancer led to 
measurable changes in left ventricle systolic function, 
but most are clinically symptomless and not affected 
in their daily activities. These changes can occur early 
in the first 3 months after initiating treatment. For 
those patients with marked decrease LVEF in the first 
3 months, echocardiography may be a necessary and 
strict follow-up (i.e. every 3 month). Symptomatic 
heart failure was noted in only 2.7% (n = 2) in our 
study. The cardiac complication group (n=14) seems 
older than the group without cardiac complication (n = 
59), but not statistically significant (65.5 ± 13.5 vs 
50.1 ± 10.9; p = 0.06). In that early period, an in-
creased incidence of mitral regurgitation was also 
noted. 
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